Drug Profile
Research programme: RecA inhibitors - Synereca Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Synereca Pharmaceuticals
- Class Small molecules
- Mechanism of Action Rec A recombinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections